RecruitingNCT03605771

Descriptive Observational Study on the Characteristics of Advanced and Metastatic Melanoma in Spain

Sponsor

Grupo Español Multidisciplinar de Melanoma

Enrollment

400 participants

Start Date

Aug 7, 2018

Study Type

OBSERVATIONAL

Conditions

Advanced Cancer Melanoma Stage IV Melanoma Stage III

Summary

This is an observational, multicentre epidemiological study with a longitudinal cohort in which information will be retrieved from medical records of patients with advanced metastatic or unresectable melanoma at first diagnosis.

Eligibility

Min Age: 18 Years

Plain Language Summary

Simplified for easier understanding

This observational study is gathering detailed information about the characteristics, treatments, and outcomes of patients in Spain with advanced or metastatic melanoma (skin cancer that has spread), to better understand how this disease behaves and how it responds to treatment in real-world settings. **You may be eligible if...** - You are a legal adult - You have been diagnosed with stage III (advanced), metastatic (spread), or inoperable melanoma for the first time after January 8, 2018 - You are willing to sign an informed consent form **You may NOT be eligible if...** - You have an earlier stage of melanoma that was fully surgically removed and has not returned as advanced/metastatic disease - You are not willing to provide consent to participate Talk to your doctor to see if this trial is right for you.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

OTHERDaily Clinical Practice

The assignment of a patient to a specific therapeutic strategy will not be decided in advance by the study protocol, but will be determined by the usual clinical practice of medicine, and the decision to prescribe a specific treatment will be clearly dissociated from the decision to include a patient in the study. No intervention will be applied to patients, either diagnostic or follow-up, other than the usual clinical practice.

Locations(39)

Hospital Virgen de los Lirios

Alcoy, Alicante, Spain

Hospital Universitario Virgen de las Nieves

Granada, Andalusia, Spain

Onconogranada

Granada, Andalusia, Spain

Hospital Universitario Regional de Málaga

Málaga, Andalusia, Spain

Hospital Universitari Vall d'Hebron

Barcelona, Barcelona, Spain

Parc Taulí

Sabadell, Barcelona, Spain

Hospital Universitario Araba Txagorritxu Victoria

Vitoria-Gasteiz, Basque Country, Spain

Hospital Universitario Marqués de Valdecilla

Santander, Cantabria, Spain

Hospital Universitario de Burgos

Burgos, Castille and León, Spain

Complejo Asistencial Universitario de Salamanca

Salamanca, Castille and León, Spain

Hospital Universitario Río Hortega

Valladolid, Castille and León, Spain

Hospital General de Ciudad Real

Ciudad Real, Castille-La Mancha, Spain

Instituto Catalán de Oncología Badalona

Badalona, Catalonia, Spain

Hospital de la Santa Creu y Sant Pau

Barcelona, Catalonia, Spain

Hospital Universitario Quirón Dexeus

Barcelona, Catalonia, Spain

Hospital Universitario San Pedro Alcántara

Cáceres, Extremadura, Spain

Onkologikoa

Donostia / San Sebastian, Guipuzcoa, Spain

Hospital San Pedro

Logroño, La Rioja, Spain

Hospital Lucus Augusti

Lugo, Lugo, Spain

Hospital Universitario La Princesa

Madrid, Madrid, Spain

Hospital Universitario La Paz

Madrid, Madrid, Spain

Hospital Universitario Ramón y Cajal

Madrid, Madrid, Spain

Hospital Universitario Puerta de Hierro-Majadahonda

Majadahonda, Madrid, Spain

Hospital Clínico Universitario Virgen de la Arrixaca

El Palmar, Murcia, Spain

Hospital Costa del Sol

Marbella, Málaga, Spain

Complejo Hospitalario de Navarra

Pamplona, Navarre, Spain

Hospital Universitario Son Llàtzer

Palma de Mallorca, Palma, Spain

Complejo Hospitalario de Pontevedra

Pontevedra, Pontevedra, Spain

Hospital Universitario de Valme

Seville, Sevilla, Spain

Hospital Virgen de la Salud

Toledo, Toledo, Spain

Hospital La Ribera

Alzira, Valencia, Spain

Hospital General Universitario de Valencia

Valencia, Valencia, Spain

Instituto Valenciano de Oncología

Valencia, Valencia, Spain

Hospital Clínico Universitario de Valladolid

Valladolid, Valladolid, Spain

Hospital Universitario Miguel Servet

Zaragoza, Zaragoza, Spain

Hospital Clínico Universitario Lozano Blesa

Zaragoza, Zaragoza, Spain

Hospital Clínico San Carlos

Madrid, Spain

Hospital General Universitario Gregorio Marañón

Madrid, Spain

Clínica Universidad de Navarra

Pamplona, Spain

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT03605771

Related Trials

Phase 1b/2 Study of Combination 177Lu Girentuximab Plus Cabozantinib and Nivolumab in Treatment naïve Patients With Advanced Clear Cell RCC

NCT056637101 location

ALIGN for Older Adults With Cancer in SNFs

NCT066162981 location

BOLSTER: Learning New Skills to Thrive

NCT069368782 locations

A Study of JZP815 Oral Capsules in Adult Participants With Advanced or Metastatic Solid Tumors Harboring Mitogen Activated Protein Kinase (MAPK) Pathway Alterations to Investigate the Safety, Dosing, and Antitumor Activity of JZP815

NCT0555704515 locations

A Study of IMC-002 in Patients With Advanced Cancer Failed to Standard Therapy

NCT052763103 locations